NCT01801852Unknown不适用
Phase 1 Study of Autologous Natural Killer T Cells Infusion in Treating Patients With Tumors
Chinese PLA General Hospital1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2013年1月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- Occurrence of study related adverse events
研究概览
简要总结
The purpose of this study is to assess the safety and effectiveness of natural killer T (NKT) cell-based autologous adoptive immunotherapy in subjects with metastatic, treatment-refractory breast cancer, glioma, hepatocellular carcinoma, squamous cell lung cancer, pancreatic cancer, colon cancer or prostate cancer.
详细描述
A randomized controlled trial on the efficacy and safety of autologous natural killer T (NKT) cells infusion treatment in advanced cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female not less than 18 years of age or over 80 years of age.
- •Life expectancy of ≥ 24 weeks as measured by the Eastern Cooperative Oncology Group (ECOG) performance status.
- •Subjects must present with one of the following disease pathologies: Breast Cancer, Glioma, Hepatocellular Cancer, Squamous Cell Lung Cancer, Pancreatic Cancer, Colon Cancer or Prostate Cancer
- •The pathology must be an assessable disease (measurable by CT scan or MRI) that is refractory to standard treatments (e.g., chemotherapy, radiation, etc.)
- •Negative for hepatitis B, hepatitis C, HIV, and CMV.
- •Subjects must present with leukocyte counts above 3,000/μL and platelet counts above 100,000/ μL.
- •Subjects must present with minimum hemoglobin levels of
- •If female, subject is surgically sterile (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), post menopausal (no menses >12 months), or using a high-efficiency method of contraception such as implant, injectable, combination oral contraceptive, intrauterine device (IUD) or sexual abstinence, or has a vasectomized partner.
- •If female of childbearing potential, subject is not pregnant, breast-feeding or planning a pregnancy during the study, and has a negative pregnancy test on screening visit.
- •Able to comprehend and sign an informed consent document and comply with the requirements of the study.
排除标准
- •No measurable malignant disease by CT scan or tumor markers.
- •Life expectancy of ≤ 24 weeks as measured by the Eastern Cooperative Oncology Group (ECOG) performance status.
- •Age of less than 18 years or over 80 years of age.
- •Documented/confirmed positive testing for hepatitis B, hepatitis C, HIV, or CMV.
- •Prior or current history of autoimmune disease.
- •Pregnant or lactating women.
- •Leukocyte count < 3,000 /μL prior to leukapheresis.
- •Platelet count < 100,000/μL prior to leukapheresis.
- •Hemoglobin levels below
- •PTT (prothrombin time) of < 12 seconds or > than 15 seconds.
- •aPTT (activated partial thromboplastin time) of < 25 seconds or > than 39 seconds.
- •Failure or refusal to sign informed consent for the study.
- •Culture fails to meet specifications for study.
- •Subject has any other medical condition that, in the opinion of the investigator, might significantly affect the ability to safely participate in the study or affect the conduct of the study.
结局指标
主要结局
Occurrence of study related adverse events
时间窗: Until week 24
defined as \>= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment
次要结局
- Anti-tumor responses to NKT cells infusions(at least once within 30 days afther completing four-cycle treatment)
研究者
Han weidong
PI
Chinese PLA General Hospital
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Autologous Natural Killer Cell Therapy for Hepatocellular CarcinomaHepatocellular CarcinomaNCT06044506Dr Cipto Mangunkusumo General Hospital3
暂停
1 期
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on CancerHepatocellular CancerSquamous Cell Lung CancerBreast CancerProstate CancerPancreatic CancerColon CancerGliomaNCT00909558Envita Medical Center, Inc.24
Unknown
1 期
Clinical Efficacy and Safety of NK and NKT Cells Infusion in Patients With Non Small Cell Lung CancerNon-small Cell Lung CancerNCT03198923Wenxiang Wang30
Unknown
1 期
NK Cells Infusion for Advanced MalignanciesImmunotherapyNCT03619954Anhui Provincial Hospital50
撤回
不适用
Evaluation of Autologous Natural Killer Cell Activity in Primary Cancer Cell CulturesSarcomaNCT05869994Sarcoma Oncology Research Center, LLC